Neuropace Inc — Cash Flow (NASDAQ:NPCE) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Cash from operating activities 24.6 M36.9 M19.7 M17.9 M 16.2 M Cash from investing activities 85.4 M23.8 M23.03 M8.99 M 2.2 M Cash from financing activities 102.53 M490 K8.13 M4.33 M 19.81 M Free cash flow 24.22 M36.3 M19.53 M17.59 M 15.93 M

뉴스

LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates

신경페이스(NPCE) 목표 주가, Leerink Partners, 19달러에서 20달러로 상향

NeuroPace stock price target raised to $20 from $19 at Leerink Partners

NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

뉴로페이스, 4분기 호실적에 UBS ’매수’ 등급 재확인 후 주가 상승

NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue

뉴로페이스, 2025년 25% 매출 성장 보고 및 꾸준한 성장 전망

NeuroPace reports 25% revenue growth for 2025, projects steady growth